Foralumab stabilized disability for 6 months in all 10 people with nonactive SPMS who took part in an expanded access program, a study found.

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's tyrosine ...

Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes” NEW ...

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...

In relapse-remitting multiple sclerosis (MS), people experience periods of high MS activity where they have more symptoms or imaging tests show inflammation. Between these periods, the condition might ...